Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in May 2021

Rhea-AI Summary

Caladrius Biosciences, a clinical-stage biopharmaceutical company focused on cellular therapies, announced participation in key industry and investor events occurring in May 2021. These include the BioEquity Europe Digital from May 17-19, BioNJ’s 11th Annual BioPartnering Conference from May 18-19, and the Advanced Therapies Congress & Expo from May 19-21. The company is advancing several treatments including CLBS16, HONEDRA, CLBS201, and OLOGO, targeting conditions like coronary microvascular dysfunction and critical limb ischemia.

BASKING RIDGE, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced its participation in several industry and investor events:

• BioEquity Europe Digital, May 17-19, 2021
  
  
• BioNJ’s 11th Annual BioPartnering Conference, May 18-19, 2021
  
  
• Advanced Therapies Congress & Expo (Virtual), May 19-21, 2021
  

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12), recipient of  orphan designation for Buerger’s Disease in the U.S. as well as  SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the FDA to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).  For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com

Media:
Real Chemistry
Kelly Wakelee
Phone: 610.639.2774
Email: kwakelee@realchemistry.com

FAQ

What events is Caladrius Biosciences (CLBS) participating in May 2021?

Caladrius Biosciences will participate in the BioEquity Europe Digital from May 17-19, BioNJ’s 11th Annual BioPartnering Conference from May 18-19, and the Advanced Therapies Congress & Expo from May 19-21.

What is CLBS16 being studied for?

CLBS16 is being studied for the treatment of coronary microvascular dysfunction and is currently in a Phase 2b study.

What designations has HONEDRA (CLBS12) received?

HONEDRA has received orphan designation for Buerger’s Disease in the U.S. and SAKIGAKE designation in Japan for the treatment of critical limb ischemia.

What is the focus of CLBS201?

CLBS201 is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

What is OLOGO (CLBS14) designated as by the FDA?

OLOGO is designated as a Regenerative Medicine Advanced Therapy (RMAT) and is in discussions with the FDA for a Phase 3 trial for disabling angina.